Functional

Dr. Golberg Institute of Functional and Aesthetic Medicine Announces Dr. Alexander Golberg Awarded Top Aesthetic Doctor in 2024 Aesthetic Everything Awards

Retrieved on: 
Tuesday, March 19, 2024
Plastic surgery, Functional, Patient, Health, Research, Publication, Aesthetics, Medicine, Medical device

New York, New York--(Newsfile Corp. - March 19, 2024) - The Dr. Golberg Institute of Functional and Aesthetic Medicine proudly declares Dr. Alexander Golberg as the recipient of the title of Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards.

Key Points: 
  • New York, New York--(Newsfile Corp. - March 19, 2024) - The Dr. Golberg Institute of Functional and Aesthetic Medicine proudly declares Dr. Alexander Golberg as the recipient of the title of Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards.
  • The recognition as Top Aesthetic Doctor in the 2024 Aesthetic Everything Awards reaffirms Dr. Golberg's position as a leading figure in the realm of aesthetic procedures.
  • At the Dr. Golberg Institute of Functional and Aesthetic Medicine, Dr. Alexander Golberg offers patients a comprehensive range of aesthetic treatments tailored to their individual needs.
  • With his dedication to innovation and patient care, Dr. Golberg contributes to the advancement of aesthetic medicine.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Retrieved on: 
Monday, April 1, 2024
Administration, Annual report, B cell, Obesity, Development, Cell, Patent, Library, Visual analogue scale, Patient, DSM-IV codes, Data monitoring committee, Form 10-K, Security (finance), Functional, Adipocyte, Type 2 diabetes, Small business, Investment, Research and development, NOA, European Patent Convention, Safety, Infrared spectroscopy correlation table, Orthopaedic Research Society, Annual general meeting, Pharmaceutical industry

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.

Key Points: 
  • MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov , and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • At December 31, 2023, BioRestorative had cash, cash equivalents and investments in marketable securities of $11.07 million.

TMS Health and Wellness Introduces Cutting-Edge Brain Scanning For Enhanced TMS Therapy Effectiveness

Retrieved on: 
Monday, April 8, 2024
Depression, Mindfulness, Magnetic resonance, Medicine, Health, Neuroimaging, Patient, TMS, Anxiety, Addiction, Chronic pain, Functional, Concierge medicine, Meditation, Wellness, Transcranial magnetic stimulation, Homeopathy, Neurofeedback, Map, Medical imaging

COSTA MESA, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- In a significant advancement for treating anxiety, depression, and other mental health conditions, TMS Health and Wellness proudly announces the integration of comprehensive brain scanning technology into its Transcranial Magnetic Stimulation (TMS) Therapy protocols. This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.

Key Points: 
  • This pioneering approach, leveraging Full Brain Scans and Functional MRI (fMRI) is set to revolutionize treatment customization, potentially elevating TMS Therapy's effectiveness to an unprecedented 90%.
  • By utilizing detailed brain imaging to map and understand each patient's unique neural patterns, TMS Health and Wellness can customize the application of TMS Therapy with greater precision than ever before.
  • The clinic's expanded services now include:
    With the introduction of brain scanning technology, TMS Health and Wellness reinforces its dedication to pioneering in the mental health space and its mission of treating the "whole person."
  • TMS Therapy enhanced with Full Brain Scans and Functional MRI is available now.

DVCon U.S. 2024 Announces Stuart Sutherland Best Paper & Best Poster Winners & Conference Highlights

Retrieved on: 
Tuesday, March 19, 2024
Shift, Infineon Technologies, Algorithm, Conference, Nvidia, UVM, Lens, PSS, Working Group, DoubleTree, Verification, Ford Motor Company, Human, Formal, Accellera, Functional, Texas Instruments, Exhibition, Paper, Cadence Design Systems, Poster, AMD, Automotive industry

The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.

Key Points: 
  • The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.
  • Overall attendance for DVCon U.S. 2024 was approximately 975, including attendees from 25 exhibiting companies.
  • “It was really an exciting time to be back at DVCon U.S.,” stated Tom Fitzpatrick, DVCon U.S. 2024 General Chair.
  • For the second consecutive year, the Poster Ninja Warrior Session determined the Stuart Sutherland Best Poster Award winners.

ProQR Announces Year End 2023 Operating and Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Trident, Eli Lilly, Exercise, ProQR, Patient, IP, Therapy, Lilly, RNA editing, Cholestasis, Rett syndrome, Research, Cardiovascular disease, Partnership, Pseudouridine, NTCP, RNA, Functional, Uridine, MECP2, Oligonucleotide, ACTB, LPL, Annual report, Conference, Patent, Biomarker, Mouse, RSRT, Eli Lilly and Company, Liver, ANGPTL3

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
  • At December 31, 2023, ProQR held cash and cash equivalents of €118.9 million, compared to €94.8 million at December 31, 2022.
  • The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
  • For further financial information for the period ended December 31, 2023, please refer to our 2023 Annual Report on Form 20-F and our Statutory Annual Report which will be available on our website, www.

Lattice to Advance Functional Safety for Automotive and Industrial Applications

Retrieved on: 
Thursday, April 4, 2024
Technology, Semiconductor, Automotive, Security, Engineering, Automotive Manufacturing, Software, Manufacturing, Hardware, Autonomous Driving, Vehicles, Automation, Partnership, Business, Lattice Semiconductor, LSCC, Edge, Field-programmable gate array, Functional, Marketing, Lattice, Safety, FPGA, Corporation

Through this enhanced collaboration, the companies will focus on bringing functional safety capabilities to customers developing safety-critical Automotive and Industrial applications.

Key Points: 
  • Through this enhanced collaboration, the companies will focus on bringing functional safety capabilities to customers developing safety-critical Automotive and Industrial applications.
  • Certified to latest safety design methodologies, Lattice Software Design tools enable our FPGAs to provide flexibility to implement and develop functional safety designs in safety-critical applications.
  • Visit Lattice’s exhibit in Hall 4, Booth #528 to experience the innovative low power FPGA solutions enabling Industrial, Automotive, and Security applications at the Edge.
  • Visit NewTec GmbH in Hall 5, Booth #178 to learn more about how safety and security can be added to Lattice FPGA solutions.

LuskinOIC Partners with the Center for Cerebral Palsy at UCLA to Host Annual Cerebral Palsy Professional Conference and Family Forum on March 23

Retrieved on: 
Tuesday, March 19, 2024
Family, Health, Consumer, Neurology, Other Health, Children, General Health, Community, Knee, Spasticity, DPT, Cerebral palsy, Conference, Neurotoxin, PCS, Doctor of Philosophy, MD, Functional, Physical disability, CP, Bangladesh Technical Education Board, Active Life: Outdoor Challenge, UCLA, Social

On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.

Key Points: 
  • On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.
  • The conference takes place during National Cerebral Palsy Awareness month.
  • Registration is required for both the Professional Conference Agenda & Registration and Family Forum Agenda & Registration .
  • Symposium sponsors include the Cerebral Palsy Foundation, the Shapiro Family Foundation, and the Tarjan Center.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, GOSS, Research, New Drug Application, Research and development, Marketing, Security (finance), Functional, Pulmonary hypertension, Entrepreneurship, PAH, PMDA, Administration, Gossamer, Patient, Public expenditure, Clinical trial, Medication, Orthostatic hypertension, G&A, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
  • “This advancement marks a significant milestone in Gossamer’s journey, and it was made possible due to the tireless efforts of the Gossamer team.
  • Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
  • Financial Results for Quarter and Full Year Ended December 31, 2023
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2023, were $296.4 million.

Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Thursday, February 15, 2024
Therapy, Division, Doctor of Philosophy, MD, Clinical trial, DMD, Functional, Neurology, Neuromuscular medicine, Conference, DM1, Safety, Muscular Dystrophy Association, RNA, Webcast, Myotonic dystrophy, Pediatrics, AOC, Publication, MDA, Volume Eight, Episcopal conference

SAN DIEGO, Feb. 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension (MARINA-OLE™) trial in people living with myotonic dystrophy type 1 (DM1) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.

Key Points: 
  • ET for a live video webcast event, which will be available on the company's website.
  • The company is hosting Volume 8 of its investor and analyst event series on March 4, 2024, beginning at 8:00 a.m.
  • ET to discuss new AOC 1001 long-term efficacy and safety data from the MARINA-OLE™ trial in people living with DM1.
  • A replay of the webcast will be archived on Avidity's website following the event.

Play, Earn, Conquer: Victory of Suckers Mega Gaming Competition!

Retrieved on: 
Saturday, February 10, 2024
VOS, Freedom, Monopoly, News, Engagement, Sucker, Functional, Non-fungible token, Esports, Longevity, NFT, JJC, Blockchain, Solana, MOBA, Environment, Cryptocurrency

Enter the gaming revolution with "Victory of Sucker," the debut game from JJCVerse.

Key Points: 
  • Enter the gaming revolution with "Victory of Sucker," the debut game from JJCVerse.
  • - Engagement and Longevity: With players dedicating over 100 hours per month to the game, “Victory of Sucker” promises longevity and a captivating gaming experience.
  • - Safe Gaming Environment: Prioritizing gameplay over investment, "Victory of Sucker" creates a safer and more responsible gaming environment, addressing concerns over speculative gaming models.
  • The excitement in the Gamefi universe reaches new heights as JJCVerse announces the "Victory of Suckers" (VOS) party, set to be one of the most significant gaming events this February.